CASTLE BIOSCIENCES INC (CSTL): Price and Financial Metrics


Today's Latest Price: $75.79 USD

3.38 (-4.27%)

Updated Jan 25 4:00pm

Add CSTL to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 77 in Medical - Services

See all "A" rated Strong Buy stocks

CSTL Stock Summary

  • With a one year PEG ratio of 0.64, Castle Biosciences Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 5.92% of US stocks.
  • Castle Biosciences Inc's stock had its IPO on July 25, 2019, making it an older stock than just 1.6% of US equities in our set.
  • The price/operating cash flow metric for Castle Biosciences Inc is higher than 94.88% of stocks in our set with a positive cash flow.
  • Stocks that are quantitatively similar to CSTL, based on their financial statements, market capitalization, and price volatility, are AXTI, PING, MLAB, KRMD, and AYX.
  • Visit CSTL's SEC page to see the company's official filings. To visit the company's web site, go to

CSTL Stock Price Chart Interactive Chart >

Price chart for CSTL

CSTL Price/Volume Stats

Current price $75.79 52-week high $84.00
Prev. close $79.17 52-week low $21.01
Day low $74.74 Volume 266,000
Day high $81.18 Avg. volume 240,247
50-day MA $62.60 Dividend yield N/A
200-day MA $47.17 Market Cap 1.53B


Castle Biosciences, Inc. provides healthcare imaging services. The Company offers diagnostic and prognostic testing solutions for cancers, as well as research and development activities. Castle Biosciences serves customers in the United States.

CSTL Latest News Stream

Event/Time News Detail
Loading, please wait...

CSTL Latest Social Stream

Loading social stream, please wait...

View Full CSTL Social Stream

Latest CSTL News From Around the Web

Below are the latest news stories about Castle Biosciences Inc that investors may wish to consider to help them evaluate CSTL as an investment opportunity.

Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Conference

Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Conference.

Yahoo | January 20, 2021

Castle Biosciences (CSTL) Investor Presentation - Slideshow

The following slide deck was published by Castle Biosciences, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | January 19, 2021

Castle Biosciences provides Q4 and FY20 update

Castle Biosciences ([[CSTL]] -5.7%) announced preliminary performance results for 4Q20 and FY20.Delivered 18,185 gene expression profile test reports in 2020.Final, expanded LCD for CMS coverage for DecisionDx-Melanoma test became effective on Dec. 6, 2020. Since the effective date, more than 90% of Medicare beneficiaries whose clinicians order DecisionDx-Melanoma as part...

Seeking Alpha | January 13, 2021

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2020 Results

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Castle--Castle today announced certain unaudited preliminary performance results for the fourth quarter and full-year 2020.

Business Wire | January 13, 2021

Castle Biosciences to Present at the 23rd Annual Needham Virtual Growth Conference

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle is scheduled to present a company overview at the 23rd Annual Needham Virtual Growth Conference on Jan. 15, 2021.

Business Wire | January 4, 2021

Read More 'CSTL' Stories Here

CSTL Price Returns

1-mo N/A
3-mo 53.67%
6-mo 92.85%
1-year 152.63%
3-year N/A
5-year N/A
YTD 12.87%
2020 95.37%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8374 seconds.